BioSpace News Archive

Magnetic Resonance Imaging (MRI) Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Magnetic Resonance Imaging (MRI) market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

DBMR released a report titled “Advanced Wound Care Market” which delivers detailed overview of the Advanced Wound Care market in terms of market segmentation by type, route of administration, end-user, and by region.

DBMR added a comprehensive research document of 350+ pages on ‘Global Augmented Reality (AR) and Virtual Reality (VR) in Healthcare Market Share, Size, Industry Trends and Forecast 2028 with detailed insights on growth factors and strategies.

X-Ray Detectors Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the X-Ray Detectors market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Ayala Pharmaceuticals, Inc. today announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI).

Orchestra BioMed™, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, and Health Sciences Acquisitions Corporation 2 announced multiple significant transactions.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee.

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN).

Oryzon Genomics, S.A. announced today the entry into a convertible bonds financing agreement (the “Issuance Agreement”) with Nice & Green in bonds convertible into new shares for a total amount of €20 Million.

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets.